New lung cancer research backed by investment
University of York spinout company, Cizzle Biotechnology, has secured venture capital funding from the White Rose Technology Seedcorn Fund to continue its development of a potential new diagnostic test and treatment for lung cancer.
The finance will enable Cizzle to progress its research into a potential new method of diagnosing and treating lung cancer, based on the discovery of the role that the protein Ciz 1 appears to play in triggering DNA replication and cell growth. As cancer is associated with abnormal cell growth, the Cizzle team ultimately hope to confirm that blocking the actions of this protein will prevent tumours from occurring or slow down the growth of existing tumours.
The company is based on the research of Dr Dawn Coverley, Lister Research Fellow in the School of Biology at the University of York, and her collaborator Dr Justin Ainscough. She says: “Our research shows that Ciz 1 plays a role in initiation of DNA replication, and recent evidence suggests that this role is disrupted in lung cancer cells. We aim to target the disrupted form of Ciz1 to generate a completely new and selective way of both diagnosing and treating small cell lung cancers. Current chemotherapies restrain the growth of all cells in the body and therefore have poorly tolerated side effects, but what we are trying to do is target the lung cancer cells specifically.”
Lung cancers are the second most common form of cancer in the West but are the most common cause of cancer death. Small cell lung cancers, associated with cigarette smoking, account for 25 per cent of all lung cancers. Cizzle plans to develop a diagnostic test and therapy to combat this specific cancer, filling a significant gap in this market. It is also possible that this technology may be applicable to other cancers.
Coverley, whose work in this area was supported by the Yorkshire Forward Bioscience Yorkshire Enterprise Fellowship scheme (BYEF) will become Chief Scientific Officer. Simon Ward, an experienced bioscience entrepreneur who set up Sheffield biotech company Molecular Skincare Ltd, then oversaw its merger into AIM listed York Pharma was Coverley’s mentor during her time within the BYEF programme. Ward will provide consultancy services to the company.
Dr Joe Wiley, Fund Manager of the White Rose Technology Seedcorn Fund said:
“This is an excellent opportunity to support a home grown company involved in new and truly innovative cancer therapy. In deciding whether to invest, we look for world class research, a committed and experienced management team and a strong market opportunity. Cizzle Biotechnology has all of these in abundance. The potential benefits to the medical sector are enormous and we are pleased to be able to support Cizzle’s research and development.”
Dr Joe Wiley | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...